Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-02-17 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S503216

Bo Yang, Huiqun Cheng, Yu Hu, Yizhu Chen, Yong Xu, Wei Huang, Yang Long, Chenlin Gao

{"title":"Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.","authors":"Bo Yang, Huiqun Cheng, Yu Hu, Yizhu Chen, Yong Xu, Wei Huang, Yang Long, Chenlin Gao","doi":"10.2147/DMSO.S503216","DOIUrl":null,"url":null,"abstract":"Background: Erectile dysfunction (ED) is considered one of the complications of diabetes mellitus (DM), affecting about 35-75% of diabetic patients. Studies suggest that anti-diabetic drugs could potentially alleviate ED in diabetics, yet the effects of different drug classes remain unknown.Objective: Our study aims to investigate the influence of various anti-diabetic drugs on ED.Materials and methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review and meta-analysis were carried out, focusing on clinical research linking anti-diabetic drugs and ED. Relevant studies were sought from PubMed, Embase, and Cochrane Library databases. Review Manager 5.4.1 facilitated meta-analysis and subgroup analysis, while Stata 15.1 was employed for sensitivity analysis to ensure result robustness.Results: An initial search yielded 3,906 articles across databases. After screening the titles and abstracts of 3,906 articles and performing a full-text review of 30 selected articles, we selected three studies for analysis ultimately. Our most significant finding is that glucagon-like peptide-1 receptor agonists (GLP-1RAs) show an advantage over metformin in improving erectile dysfunction in diabetic patients (Z = 2.41, P = 0.02), with a particularly notable effect observed in patients with higher BMI or obesity (Z = 2.26, P = 0.02). This suggests that GLP-1RAs may offer a promising therapeutic option for this patient population. Additionally, thiazolidinediones may enhance sexual function, although their safety and efficacy require further confirmation. Acarbose, insulin, and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) also show potential for positively impacting ED, but more research is needed to establish their efficacy. Finally, the impact of metformin and sulfonylureas on ED remains uncertain, with mixed evidence from existing studies.Conclusion: In conclusion, GLP-1RAs demonstrate an advantage over metformin in improving erectile dysfunction in diabetic patients. Other antidiabetic drugs also show potential for enhancing erectile function in this population, but further extensive clinical trials are needed to address knowledge gaps and safety concerns.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"467-478"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844210/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S503216","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Erectile dysfunction (ED) is considered one of the complications of diabetes mellitus (DM), affecting about 35-75% of diabetic patients. Studies suggest that anti-diabetic drugs could potentially alleviate ED in diabetics, yet the effects of different drug classes remain unknown.

Objective: Our study aims to investigate the influence of various anti-diabetic drugs on ED.

Materials and methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review and meta-analysis were carried out, focusing on clinical research linking anti-diabetic drugs and ED. Relevant studies were sought from PubMed, Embase, and Cochrane Library databases. Review Manager 5.4.1 facilitated meta-analysis and subgroup analysis, while Stata 15.1 was employed for sensitivity analysis to ensure result robustness.

Results: An initial search yielded 3,906 articles across databases. After screening the titles and abstracts of 3,906 articles and performing a full-text review of 30 selected articles, we selected three studies for analysis ultimately. Our most significant finding is that glucagon-like peptide-1 receptor agonists (GLP-1RAs) show an advantage over metformin in improving erectile dysfunction in diabetic patients (Z = 2.41, P = 0.02), with a particularly notable effect observed in patients with higher BMI or obesity (Z = 2.26, P = 0.02). This suggests that GLP-1RAs may offer a promising therapeutic option for this patient population. Additionally, thiazolidinediones may enhance sexual function, although their safety and efficacy require further confirmation. Acarbose, insulin, and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) also show potential for positively impacting ED, but more research is needed to establish their efficacy. Finally, the impact of metformin and sulfonylureas on ED remains uncertain, with mixed evidence from existing studies.

Conclusion: In conclusion, GLP-1RAs demonstrate an advantage over metformin in improving erectile dysfunction in diabetic patients. Other antidiabetic drugs also show potential for enhancing erectile function in this population, but further extensive clinical trials are needed to address knowledge gaps and safety concerns.

查看原文本刊更多论文

抗糖尿病药物对勃起功能障碍的影响：系统回顾和荟萃分析。

背景：勃起功能障碍（ED）被认为是糖尿病（DM）的并发症之一，约占糖尿病患者的35-75%。研究表明，抗糖尿病药物可能潜在地减轻糖尿病患者的ED，但不同药物类别的效果尚不清楚。目的：本研究旨在探讨各种降糖药物对ED的影响。材料和方法：根据PRISMA （Preferred Reporting Items for Systematic Reviews and meta-analysis）指南，对降糖药物与ED的临床研究进行系统评价和荟萃分析，从PubMed、Embase和Cochrane Library数据库中检索相关研究。meta分析和亚组分析采用Review Manager 5.4.1，敏感性分析采用Stata 15.1，以保证结果的稳健性。结果：最初的搜索在数据库中产生了3906篇文章。在筛选了3,906篇文章的标题和摘要，并对其中30篇文章进行了全文综述后，我们最终选择了3篇研究进行分析。我们最重要的发现是胰高血糖素样肽-1受体激动剂（GLP-1RAs）在改善糖尿病患者勃起功能障碍方面优于二甲双胍（Z = 2.41, P = 0.02），在BMI较高或肥胖患者中效果尤其显著（Z = 2.26, P = 0.02）。这表明GLP-1RAs可能为这类患者提供一个有希望的治疗选择。此外，噻唑烷二酮类药物可增强性功能，但其安全性和有效性有待进一步证实。阿卡波糖、胰岛素和钠-葡萄糖共转运蛋白-2抑制剂（SGLT-2i）也显示出对ED有积极影响的潜力，但需要更多的研究来确定它们的功效。最后，二甲双胍和磺脲类药物对ED的影响仍不确定，现有研究的证据不一。结论：总之，GLP-1RAs在改善糖尿病患者勃起功能障碍方面优于二甲双胍。其他抗糖尿病药物也显示出增强该人群勃起功能的潜力，但需要进一步广泛的临床试验来解决知识差距和安全性问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.